FDA updates early Alzheimer’s drug development guidance to add support for biomarkers, surrogate endpoints
Regulatory NewsJeff Craven
Biologics/ biosimilars/ vaccinesClinical TrialsPharmaceuticalsResearch, Design and DevelopmentUnited StatesRegulatory NewsJeff CravenBiologics/ biosimilars/ vaccinesClinical TrialsPharmaceuticalsResearch, Design and DevelopmentUnited States